| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Probiotix Health PLC - Appointment of Aquis Corporate Adviser | 8 | RNS | ||
| 20.10. | ProBiotix partners with Wellizen on new cardiometabolic health capsule | 1 | Alliance News | ||
| 20.10. | Probiotix Health PLC - New Commercial Partnership in Australia | 1 | RNS | ||
| 14.10. | ProBiotix partners with RevivaBio on new cholesterol-lowering product | 1 | Alliance News | ||
| 14.10. | Probiotix Health PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 14.10. | Probiotix Health PLC - New Commercial Partnership in Sweden | 1 | RNS | ||
| PROBIOTIX HEALTH Aktie jetzt für 0€ handeln | |||||
| 13.10. | ProBiotix Health says sales rise amid "well received" new products | 2 | Alliance News | ||
| 13.10. | Probiotix Health PLC - Q3 2025 Trading Update and Grant of Options | 1 | RNS | ||
| 08.09. | ProBiotix Health narrows loss amid 'record' first half performance | 5 | Alliance News | ||
| 08.09. | Probiotix Health PLC - Unaudited Interim Results to 30 June 2025 | 1 | RNS | ||
| 15.07. | Probiotix Health PLC - Trading Update and Notice of Results | 1 | RNS | ||
| 27.06. | Probiotix Health PLC - Result of AGM and Notice of Trading Update | 1 | RNS | ||
| 09.06. | Probiotix Health PLC - PDMR Shareholding | 1 | RNS | ||
| 05.06. | Probiotix Health PLC - Notice of Annual General Meeting - Clarification | - | RNS | ||
| 30.05. | Probiotix Health PLC - Director/PDMR Shareholding | - | RNS | ||
| 30.05. | Probiotix Health PLC - Notice of AGM | - | RNS | ||
| 29.05. | Probiotix Health reports revenue growth and robust margins for 2024 | 2 | Investing.com | ||
| 29.05. | Probiotix Health verzeichnet Umsatzwachstum und solide Margen für 2024 | 2 | Investing.com Deutsch | ||
| 29.05. | Probiotix Health PLC - Final Results | - | RNS | ||
| 07.05. | Probiotix Health PLC - Notice of Results and Investor Presentation | 1 | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRAIN BIOTECH | 2,210 | -2,21 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,406 | +1,50 % | MustGrow Biologics Corp.: MustGrow Announces Grant of RSUs and DSUs | Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors... ► Artikel lesen | |
| OPTIBIOTIX HEALTH | 0,091 | 0,00 % | Director dealings: Optibiotix Health finance director snaps up shares | ||
| AVIDITY BIOSCIENCES | 69,97 | +42,36 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| QIAGEN | 41,860 | -1,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,290 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 7,124 | +2,18 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,170 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| MAPLIGHT THERAPEUTICS | 18,050 | 0,00 % | MapLight Therapeutics Prices IPO Of 14.75 Mln Shares At $17.00/shr | WASHINGTON (dpa-AFX) - MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company focused on
improving the lives of patients suffering from debilitating central nervous
system... ► Artikel lesen | |
| NUVALENT | 97,95 | +4,88 % | Piper Sandler erhöht Kursziel für Nuvalent auf 128 US-Dollar wegen ALK-Potenzial | ||
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 186,82 | +7,53 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 58,53 | +2,16 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ZENAS BIOPHARMA | 31,500 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis | - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,470 | +1,04 % | Summit Therapeutics: A Risky Bet in the Biotech Arena? |